{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:04:34Z","timestamp":1792807474857,"version":"4.5.0"},"reference-count":83,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antimicrobial resistance (AMR) remains a growing threat to public health and healthcare systems. In 2015, Canada published its first AMR Priority Pathogen List. In 2025, an updated list was developed to reflect evolving resistance trends, emerging pathogens, and advances in national surveillance capacity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To conduct a qualitative analysis of the 2025 AMR prioritization results to evaluate the strengths and limitations of current Canadian AMR surveillance systems in detecting and monitoring high-risk pathogens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>As described in a companion paper, 29 AMR pathogens were prioritized using a multi-criteria decision analysis (MCDA) framework, informed by Canadian data from 2017 to 2022. Pathogens were assessed across nine weighted criteria, including incidence, treatability, and a newly integrated health equity dimension. Criteria weights were derived from expert consensus, and sensitivity analyses confirmed ranking stability. This paper presents a qualitative analysis examining how well these pathogens are captured by existing national surveillance systems and highlights data integration gaps.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The 2025 prioritization identified significant shifts in Canada\u2019s AMR landscape, including the emergence of\n                      <jats:italic>Candida auris<\/jats:italic>\n                      , drug-resistant\n                      <jats:italic>Neisseria gonorrhoeae<\/jats:italic>\n                      , and\n                      <jats:italic>Mycoplasma genitalium<\/jats:italic>\n                      as high-priority threats. Canada\u2019s approach aligns closely with international frameworks (e.g., WHO, CDC), enhancing its global relevance. AMRNet, a national laboratory-based AMR surveillance platform, has the capacity to eventually capture 90% of prioritized pathogens, and over half of pathogens are currently covered by enhanced national systems that integrate laboratory and epidemiologic data. A quadrant-based assessment revealed strong coverage for several pathogens, but persistent gaps remain, particularly for those lacking routine diagnostics. Over one-third of prioritized pathogens disproportionately affect marginalized populations, underscoring the importance of integrating disaggregated sociodemographic data into surveillance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Canada has made meaningful progress toward integrated, equity-informed AMR surveillance. Continued investment and collaboration are essential to close persistent data gaps, improve responsiveness, and support targeted public health action\n                      <jats:bold>.<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0341133","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T18:25:23Z","timestamp":1771439123000},"page":"e0341133","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["AMR surveillance in Canada: Insights from the 2025 Priority Pathogen List"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0929-0422","authenticated-orcid":true,"given":"Kahina","family":"Abdesselam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia K.","family":"Muchaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aanchal","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5252-1256","authenticated-orcid":true,"given":"Raymond-Jonas","family":"Ngendabanka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanchana","family":"Amaratunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakhi","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallis","family":"Rudnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Louise","family":"Crago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Lary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"issue":"13","key":"pone.0341133.ref001","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.3390\/healthcare11131946","article-title":"Antimicrobial resistance: a growing serious threat for global public health","volume":"11","author":"MA Salam","year":"2023","journal-title":"Healthcare (Basel)"},{"issue":"9","key":"pone.0341133.ref002","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.3390\/microorganisms12091920","article-title":"An overview of the recent advances in antimicrobial resistance","volume":"12","author":"M Oliveira","year":"2024","journal-title":"Microorganisms"},{"key":"pone.0341133.ref003","volume-title":"When antibiotics fail: the expert panel on the potential socio-economic impacts of antimicrobial resistance in Canada","author":"BB Finlay","year":"2019"},{"key":"pone.0341133.ref004","author":"PHAO Canada","year":"2023","journal-title":"Pan-Canadian Action Plan on Antimicrobial Resistance"},{"key":"pone.0341133.ref005","author":"WH Organization","year":"2016"},{"key":"pone.0341133.ref006","volume-title":"17 Sustainable Development Goals","author":"U Nations","year":"2023"},{"key":"pone.0341133.ref007","volume-title":"Global health security agenda","author":"GHS Agenda","year":"2014"},{"key":"pone.0341133.ref008","volume-title":"Minister of Health Mandate Letter","author":"J Trudeau","year":"2021"},{"key":"pone.0341133.ref009","volume-title":"Canadian Antimicrobial Resistance Surveillance System (CARSS) Report 2022","author":"PHAO Canada","year":"2022"},{"key":"pone.0341133.ref010","volume-title":"Canadian Antimicrobial Resistance Surveillance System (CARSS)","author":"PHAO Canada","year":"2024"},{"issue":"11","key":"pone.0341133.ref011","doi-asserted-by":"crossref","first-page":"227","DOI":"10.14745\/ccdr.v42i11a02","article-title":"Antimicrobial use and antimicrobial resistance trends in Canada: 2014","volume":"42","author":"M Ebrahim","year":"2016","journal-title":"Can Commun Dis Rep"},{"issue":"9","key":"pone.0341133.ref012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0330128","article-title":"Canada\u2019s 2025 AMR priority pathogens: Evidence-based ranking and public health implications","volume":"20","author":"K Abdesselam","year":"2025","journal-title":"PLoS One"},{"key":"pone.0341133.ref013","doi-asserted-by":"crossref","first-page":"522","DOI":"10.14745\/ccdr.v48i1112a05","article-title":"Overview of Canada\u2019s Antimicrobial Resistance Network (AMRNet): A data-driven One Health approach to antimicrobial resistance surveillance","volume":"48","author":"W Rudnick","year":"2022","journal-title":"Can Commun Dis Rep"},{"key":"pone.0341133.ref014","doi-asserted-by":"crossref","first-page":"506","DOI":"10.14745\/ccdr.v48i1112a03","article-title":"The Canadian Nosocomial Infection Surveillance Program: Keeping an eye on antimicrobial resistance in Canadian hospitals since 1995","volume":"48","year":"2022","journal-title":"Can Commun Dis Rep"},{"key":"pone.0341133.ref015","author":"PHAO Canada","year":"2025"},{"issue":"4","key":"pone.0341133.ref016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125155","article-title":"An assessment of antimicrobial resistant disease threats in Canada","volume":"10","author":"MJ Garner","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"pone.0341133.ref017","first-page":"1","article-title":"One Health surveillance of antimicrobial resistance and use by the Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS)","volume":"17","author":"AL Bosman","year":"2021","journal-title":"Can Commun Dis Rep"},{"key":"pone.0341133.ref018","author":"Go Canada"},{"key":"pone.0341133.ref019","author":"GO Canada","year":"2025"},{"key":"pone.0341133.ref020","author":"GO Canada","year":"2021"},{"key":"pone.0341133.ref021","author":"PHAO Canada","year":"2023"},{"key":"pone.0341133.ref022","volume-title":"Candida auris","author":"PH Ontario","year":"2023"},{"key":"pone.0341133.ref023","volume-title":"Frequently Asked Questions Carbapenemase-Producing Enterobacteriaceae (CPE)","author":"PH Ontario","year":"2019"},{"key":"pone.0341133.ref024","volume-title":"Surveillance Report Shigella Antimicrobial Resistance","author":"PH Ontario","year":"2023"},{"key":"pone.0341133.ref025","volume-title":"Evidence review and revised recommendations for the control of vancomycin-resistant enterococci in all Ontario health care facilities","author":"Provincial Infectious Diseases Advisory Committee","year":"2019"},{"key":"pone.0341133.ref026","volume-title":"Carbapenemaseproducing Organisms (CPO) Protocol","author":"AH Services","year":"2025"},{"issue":"729","key":"pone.0341133.ref027","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3399\/bjgp23X732537","article-title":"Spotlight on drug-resistant Shigella: raising awareness within general practice","volume":"73","author":"H Charles","year":"2023","journal-title":"Br J Gen Pract"},{"issue":"8","key":"pone.0341133.ref028","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3201\/eid2908.230323","article-title":"Multidrug-Resistant Shigella sonnei Bacteremia among Persons Experiencing Homelessness, Vancouver, British Columbia, Canada","volume":"29","author":"A Stefanovic","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"pone.0341133.ref029","volume-title":"Interim guidance for the treatment of uncomplicated gonococcal infections","author":"NACoSTaB-BI","year":"2024"},{"key":"pone.0341133.ref030","author":"SHSC","year":"2024"},{"key":"pone.0341133.ref031","author":"PHAo Canada","year":"2021"},{"key":"pone.0341133.ref032","volume-title":"Canadian guidelines on sexually transmitted infections","author":"PHAO Canada","year":"2008"},{"key":"pone.0341133.ref033","volume-title":"Chlamydia and LGV guide: Key information and resources","author":"PHAO Canada","year":"2025"},{"issue":"11","key":"pone.0341133.ref034","doi-asserted-by":"crossref","DOI":"10.1097\/CCM.0000000000005357","article-title":"Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021","volume":"49","author":"L Evans","year":"2021","journal-title":"Crit Care Med"},{"key":"pone.0341133.ref035","volume-title":"Anti-infective guidelines for community-acquired infection","author":"M Health","year":"2024"},{"key":"pone.0341133.ref036","author":"Infections NACoSTaB-B","year":"2024"},{"issue":"3","key":"pone.0341133.ref037","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"C Liu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pone.0341133.ref038","first-page":"71","article-title":"Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection","volume":"3","author":"VG Loo","year":"2018","journal-title":"J Assoc Med Microbiol Infect Dis Canada"},{"issue":"4","key":"pone.0341133.ref039","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciw444","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"TF Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"pone.0341133.ref040","article-title":"Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections","author":"PD Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"pone.0341133.ref041","volume-title":"WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance, to guide research, development, and strategies to prevent and control antimicrobial resistance: World Health Organization","author":"O World Health","year":"2024"},{"key":"pone.0341133.ref042","first-page":"67","volume-title":"Antibiotic resistance threats in the United States","author":"CDC","year":"2019"},{"key":"pone.0341133.ref043","volume-title":"Microsoft Excel","author":"M Corporation","year":"2024"},{"key":"pone.0341133.ref044","volume-title":"R: A language and environment for statistical computing","author":"RDC Team","year":"2010"},{"key":"pone.0341133.ref045","volume-title":"Python. Python 3.13.5 ed","author":"PS Foundation"},{"key":"pone.0341133.ref046","volume-title":"Canva [Internet]","author":"Canva"},{"key":"pone.0341133.ref047","volume-title":"Canadian antimicrobial resistance surveillance system 2017 report","author":"PHAO Canada","year":"2017"},{"key":"pone.0341133.ref048","author":"GO Canada","year":"2025"},{"key":"pone.0341133.ref049","author":"Go Canada","year":"2024"},{"key":"pone.0341133.ref050","author":"Go Canada","year":"2025"},{"key":"pone.0341133.ref051","volume-title":"Canadian Public Health Laboratory Network Strategic Plan 2016-2020","author":"Go Canada","year":"2018"},{"key":"pone.0341133.ref052","author":"CARA"},{"key":"pone.0341133.ref053","article-title":"Ten years of the CANWARD Study (2007-16)","volume":"74","author":"Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"pone.0341133.ref054","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1155\/2008\/162493","article-title":"Community-associated methicillin-resistant Staphylococcus aureus: Continuing to evolve","volume":"19","author":"B Johnston","year":"2008","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"pone.0341133.ref055","volume-title":"WHO fungal priority pathogens list to guide research, development and public health action","author":"O World Health","year":"2022"},{"issue":"11","key":"pone.0341133.ref056","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S1473-3099(20)30154-7","article-title":"Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis","volume":"20","author":"DA Machalek","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"pone.0341133.ref057","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/cid\/ciad405","article-title":"Mycoplasma genitalium in the US (MyGeniUS): Surveillance Data From Sexual Health Clinics in 4 US Regions","volume":"77","author":"LE Manhart","year":"2023","journal-title":"Clin Infect Dis"},{"key":"pone.0341133.ref058","first-page":"477","article-title":"Mycoplasma genitalium infection among gay, bisexual and other men who have sex with men in Montr\u00e9al, Canada","volume":"49","author":"A-S L\u00ea","year":"2023","journal-title":"Can Commun Dis Rep"},{"issue":"9","key":"pone.0341133.ref059","doi-asserted-by":"crossref","first-page":"388","DOI":"10.14745\/ccdr.v49i09a05","article-title":"Antimicrobial susceptibilities of Neisseria gonorrhoeae in Canada, 2021","volume":"49","author":"P Sawatzky","year":"2023","journal-title":"Canada Commun Dis Rep"},{"issue":"11","key":"pone.0341133.ref060","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1139\/cjm-2019-0210","article-title":"Continuing surveillance of invasive Haemophilus influenzae disease in northwestern Ontario emphasizes the importance of serotype a and non-typeable strains as causes of serious disease: a Canadian Immunization Research Network (CIRN) Study","volume":"65","author":"A Cerqueira","year":"2019","journal-title":"Can J Microbiol"},{"issue":"5","key":"pone.0341133.ref061","doi-asserted-by":"crossref","first-page":"121","DOI":"10.14745\/ccdr.v50i05a02","article-title":"Invasive pneumococcal disease surveillance in Canada, 2021-2022","volume":"50","author":"A Griffith","year":"2024","journal-title":"Can Commun Dis Rep"},{"issue":"2","key":"pone.0341133.ref062","article-title":"Ceftriaxone-Resistant Neisseria gonorrhoeae, Canada, 2017 - PubMed","volume":"24","author":"L B","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"pone.0341133.ref063","doi-asserted-by":"crossref","first-page":"571","DOI":"10.14745\/ccdr.v48i1112a10","article-title":"Antimicrobial susceptibilities of Neisseria gonorrhoeae in Canada, 2020","volume":"48","author":"R Thorington","year":"2022","journal-title":"Can Commun Dis Rep"},{"issue":"9","key":"pone.0341133.ref064","doi-asserted-by":"crossref","first-page":"407","DOI":"10.14745\/ccdr.v48i09a05","article-title":"Invasive group A streptococcal disease surveillance in Canada, 2020","volume":"48","author":"A Golden","year":"2022","journal-title":"CCDR"},{"issue":"3","key":"pone.0341133.ref065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1155\/2015\/853287","article-title":"Antimicrobial susceptibility of Canadian isolates of Helicobacter pylori in Northeastern Ontario","volume":"26","author":"NF Eng","year":"2015","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"11","key":"pone.0341133.ref066","doi-asserted-by":"crossref","first-page":"491","DOI":"10.14745\/ccdr.v47i11a09","article-title":"Invasive bacterial diseases in northern Canada, 1999 to 2018","volume":"47","author":"G Huang","year":"2021","journal-title":"Can Commun Dis Rep"},{"issue":"6","key":"pone.0341133.ref067","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1139\/cjm-2022-0208","article-title":"Epidemiology of invasive Haemophilus influenzae disease in northwestern Ontario: comparison of invasive and noninvasive H. influenzae clinical isolates","volume":"69","author":"M Ulanova","year":"2023","journal-title":"Can J Microbiol"},{"issue":"9","key":"pone.0341133.ref068","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1128\/JCM.01128-15","article-title":"Emergence of Serotype IV Group B Streptococcus Adult Invasive Disease in Manitoba and Saskatchewan, Canada, is driven by clonal sequence type 459 strains","volume":"53","author":"S Teatero","year":"2015","journal-title":"J Clin Microbiol"},{"key":"pone.0341133.ref069","first-page":"109","article-title":"Chapter 8: drug-resistant tuberculosis","volume":"6","author":"SK Brode","year":"2022","journal-title":"Can J Resp Critic Care Sleep Med"},{"key":"pone.0341133.ref070","first-page":"229","article-title":"Chapter 15: Monitoring tuberculosis program performance","volume":"6","author":"C Heffernan","year":"2022","journal-title":"Can J Resp Critic Care Sleep Med"},{"issue":"5","key":"pone.0341133.ref071","article-title":"Directly observed therapy for treating tuberculosis","volume":"2015","author":"J Karumbi","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0341133.ref072","author":"PHAo Canada","year":"2024"},{"issue":"4","key":"pone.0341133.ref073","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/tropicalmed10040115","article-title":"The state of antimicrobial resistance of Gram-Negative Bacilli in Canada","volume":"10","author":"J Li","year":"2025","journal-title":"Trop Med Infect Dis"},{"issue":"1","key":"pone.0341133.ref074","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/microorganisms8010137","article-title":"Genomic analysis of carbapenemase-producing extensively drug-resistant Klebsiella pneumoniae isolates reveals the horizontal spread of p18-43_01 plasmid encoding blaNDM-1 in South Africa","volume":"8","author":"Y Ramsamy","year":"2020","journal-title":"Microorganisms"},{"issue":"9","key":"pone.0341133.ref075","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41579-022-00720-1","article-title":"Tackling the emerging threat of antifungal resistance to human health","volume":"20","author":"MC Fisher","year":"2022","journal-title":"Nat Rev Microbiol"},{"issue":"8","key":"pone.0341133.ref076","article-title":"Mycoplasma genitalium Incidence, Coinfection, and Antibiotic Resistance: A Prospective Study at a Walk-In Clinic in Los Angeles County, CA","volume":"11","author":"AC Sukhija-Cohen","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"pone.0341133.ref077","first-page":"7537318","article-title":"Mycoplasma genitalium: an emerging sexually transmitted infection","volume":"2016","author":"JL Munoz","year":"2016","journal-title":"Scientifica (Cairo)"},{"key":"pone.0341133.ref078","volume-title":"Division of HIVAE, Surveillance, National HIV, Retrovirology L. HIV-1 strain and primary drug resistance in Canada: surveillance report to. HIV-1 strain and primary drug resistance in Canada: surveillance report to","author":"Centre for Infectious Disease P, Control","year":"2001"},{"key":"pone.0341133.ref079","author":"(BC-CfE) BCCfEiHA"},{"key":"pone.0341133.ref080","author":"CATIE","year":"2024"},{"issue":"5","key":"pone.0341133.ref081","doi-asserted-by":"crossref","first-page":"235","DOI":"10.14745\/ccdr.v49i05a09","article-title":"Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2017\u20132021","volume":"49","author":"P Canadian Nosocomial Infection Surveillance","year":"2023","journal-title":"Canada Commun Dis Rep"},{"key":"pone.0341133.ref082","author":"Go Canada","year":"2024"},{"key":"pone.0341133.ref083","volume-title":"Overview of influenza monitoring in Canada","author":"Go Canada","year":"2024"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T18:25:35Z","timestamp":1771439135000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341133"}},"subtitle":[],"editor":[{"given":"Mengistu Hailemariam","family":"Zenebe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":83,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0341133","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]}}}